Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)

Whitehawk Therapeutics (WHWK) has reported Gross Margin for 5 consecutive years, with 89.36% the latest figure, recorded in Q1 2025.

• In Q1 2025, Gross Margin rose 154.0% year-over-year to 89.36%; the TTM figure through Dec 2025 stood at 89.36% (up 100.0% YoY), while the FY2025 annual figure was 89.36%, up 100.0% from the prior year.
• Gross Margin was little changed at 89.36% in Q1 2025 per WHWK's latest filing, from 89.09% in the prior quarter.
• Across five years, Gross Margin topped out at 100.0% in Q4 2021 and bottomed at 85.35% in Q4 2023.
• Historically, Gross Margin has averaged 90.05% across 5 years, with a median of 89.23% in 2024.
• Annual changes were most pronounced in 2023 — Gross Margin sank 1041 bps — and 2024, when it soared 374 bps.
• Whitehawk Therapeutics' Gross Margin stood at 100.0% in 2021, then decreased by 4 bps to 95.75% in 2022, then fell by 11 bps to 85.35% in 2023, then rose by 4 bps to 89.09% in 2024, then climbed by 0 bps to 89.36% in 2025.
• Business Quant data shows WHWK's Gross Margin at 89.36% in Q1 2025, 89.09% in Q4 2024, and 88.85% in Q3 2024.